Abstract
Deregulation of brain Ca2+ homeostasis is linked with oxidative stress, mitochondrial dysfunction, neurodegeneration, loss of synaptic plasticity, and cholinergic deficits. Earlier chronic administration of calcium channel blockers (L-type CCBs) has afforded relief in Alzheimer’s disease (AD) symptoms. Azelnidipine (AZL) is a long duration L-type Ca2+ channel blocker recently included in anti-hypertensive therapy. The present study reveals the role of AZL in the management of ICV-STZ induced AD in rats. Wistar rats of either sex (aged 12–15 weeks and weight range 260–280 g) were divided into 6 groups in single blind fashion and stereotaxic surgery was performed. Streptozotocin (3 mg/kg) was injected (ICV) in five groups and one group was administered with ACSF. AZL was administered (1.5, 3 and 6 mg/kg; p.o.) to separate groups of ICV-STZ pre-treated rats for 14 successive days. Memory of rats was measured using elevated plus maze and novel object recognition task. After behavioral evaluation, the animals were sacrificed and whole brains were isolated for estimation of AChE activity, TBARS and GSH levels. ICV-STZ treatment increased the brain AChE activity, TBARS level, decreased GSH level, and thereby impaired the memory of rats. The Ca2+ antagonistic property of AZL attenuated the STZ induced derangement of biochemical parameters and resurrected the memory functions in rats. This study exhibited that long-term blockade of the L-type Ca2+ channels using azelnidipine mitigates AD type dementia owing to its neuroprotective and antioxidant properties.
Similar content being viewed by others
REFERENCES
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E.K., Jones, P.K., Ghanbari, H., Wataya, T., Shimohama, S., Chiba, S., Atwood, C.S., Petersen, R.B., and Smith, M.A., J. Neuropathol. Exp. Neurol., 2001, vol. 60, pp. 759–767.
Görlach, A., Bertram, K., Hudecova, S., and Krizanova, O., Redox Biol., 2015, vol. 6, pp. 260–271.
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R.L., Atwood, C.S., Johnson, A.B., Kress, Y., Vinters, H.V., Tabaton, M., Shimohama, S., Cash, A.D., Siedlak, S.L., Harris, P.L., Jones, P.K., Petersen, R.B., Perry, G., and Smith, M.A., J. Neurosci., 2001, vol. 21, pp. 3017–3023.
Khachaturian, Z.S., Ann. N. Y. Acad. Sci., 1989, vol. 568, pp. 1–4.
Green, K.N. and LaFerla, F.M., Neuron, 2008, vol. 59, pp. 190–194.
Green, K.N., J. Cell. Mol. Med., 2009, vol. 13, pp. 2787–2799.
Berridge, M.J., Biochem. Soc. Trans., 2012, vol. 40, pp. 297–309.
Tabet, F., Savoia, C., Schiffrin, E.L., and Touyz, R.M., J. Cardiovasc. Pharmacol., 2004, vol. 44, pp. 200–208.
Brookes, P.S., Yoon, Y., Robotham, J.L., Anders, M.W., Sheu, S.S., Am. J. Physiol. Cell Physiol., 2004, vol. 287, pp. C817–C833.
Foskett, J.K. and Philipson, B., J. Mol. Cell Cardiol., 2015, vol. 78, pp. 3–8.
Seidlmayer, L.K., Juettner, V.V., Kettlewell, S., Pavlov, E.V., Blatter, L.A., and Dedkova, E.N., Cardiovasc. Res., 2015, vol. 106, pp. 237–248.
Nimmrich, V. and Eckert, A., Br. J. Pharmacol., 2013, vol. 169, pp. 1203–1210.
Nakano, K., Egashira, K., Ohtani, K., Gang, Z., Iwata, E., Miyagawa, M., and Sunagawa, K., Atherosclerosis, 2008, vol. 196, pp. 172–179.
Bagheri, M., Jahromi, B.M., Mirkhani, H., Solhjou, Z., Noorafshan, A., Zamani, A., and Amirghofran, Z., J. Surg. Res., 2011, vol. 169, pp. e101–e107.
Godfraind, T., Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2005, vol. 360, pp. 2259–2272.
Shinomiya, K., Mizushige, K., Fukunaga, M., Masugata, H., Ohmori, K., Kohno, M., and Senda, S., J. Int. Med. Res., 2004, vol. 32, pp. 170–175.
Yamagishi, S., Inagaki, Y., Nakamura, K., and Imaizumi, T., J. Cardiovasc. Pharmacol., 2004, vol. 43, pp. 724–730.
Batova, S., DeWever, J., Godfraind, T., Balligand, J.L., Dessy, C., and Feron, O., Cardiovasc. Res., 2006, vol. 71, pp. 478–485.
Kario, K., Sato, Y., Shirayama, M., Takahashi, M., Shiosakai, K., Hiramatsu, K., Komiya, M., and Shimada, K., Drugs R. D., 2013, vol. 13, pp. 63–73.
Chen, B.L., Zhang, Y.Z., Luo, J.Q., and Zhang, W., Ther. Clin. Risk Manag., 2015, vol. 11, pp. 309–318.
Sharma, M. and Gupta, Y.K., Life Sci., 2002, vol. 71, pp. 2489–2498.
Paxinos, G., Watson, C.R., and Emson, P.C., J. Neurosci. Methods., 1980, vol. 3, pp. 129–149.
Kumar, M., and Bansal, N., Behav. Brain Res., 2018, vol. 351, pp. 4–16.
Lukic-Panin, V., Kamiya, T., Zhang, H., Hayashi, T., Tsuchiya, A., Sehara, Y., Deguchi, K., Yamashita, T., and Abe, K., Brain Res., 2007, vol. 1176, pp. 143–150.
Bansal, N, and Parle, M., J. Med. Food., 2010, vol. 13, pp. 1293–1300.
Shastry, R., Ullal, S.D., Karkala, S., Rai, S., and Gadgade, A., Indian J. Pharmacol., 2016, vol. 48, pp. 681–686.
Itoh, J., Nabeshima, T., and Kameyama, T., Psychopharmacology, 1990, vol. 101, pp. 27–33.
Reddy, D.S. and Kulkarni, S.K., Brain Res., 1998, vol. 799, pp. 215–229.
Vasudevan, M., and Parle, M., Pharm. Biol., 2007, vol. 45, pp. 267–273.
Ennaceur, A. and Delacour, J., Behav. Brain Res., 1988, vol. 31, pp. 47–59.
Abada, Y.K., Nguyen, H.P., Schreiber, R., and Ellenbroek, B., PLoS One, 2013, vol. 8, p. e68584.
Ohkawa, H., Ohishi, N., and Yagi, K., Anal. Biochem., 1979, vol. 95, pp. 351–358.
Ellman, G.L., Arch. Biochem. Biophys., 1959, vol. 82, pp. 70–74.
Ellman, G.L., Courtney, K.D., Andres, V., and Featherstone, R.M., Biochem. Pharmacol., 1961, vol. 7, pp. 88-95.
Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J., J. Biol. Chem., 1951, vol. 193, pp. 265–275.
Grieb, P., Mol. Neurobiol., 2016, vol. 53, pp. 1741–1752.
Ahn, C., An, B.S., and Jeung, E.B., Mol. Cell. Endocrinol., 2015, vol. 412, pp. 302–308.
Gutierres, J.M., Carvalho, F.B., Schetinger, M.R.C., Marisco, P., Agostinho, P., Rodrigues, M., Rubin, M.A., Schmatz, R., da Silva, C.R., de P Cognato, G., Farias, J.G., Signor, C., Morsch, V.M., Mazzanti, C.M., Bogo, M., Bonan, C.D., and Spanevello, R., Life Sci., 2014, vol. 96, pp. 7–17.
Correia, S.C., Santos, R.X., Santos, M.S., Casadesus, G., Lamanna, J.C., Perry, G., Smith, M.A., and Moreira, P.I., Curr. Alzheimer. Res., 2013, vol. 10, pp. 406–419.
Jayant, S., Sharma, B.M., and Sharma, B., Brain Res., 2016, vol. 1642, pp. 397–408.
Bradley-Whitman, M.A. and Lovell, M.A., Arch. Toxicol., 2015, vol. 89, pp. 1035–1044.
Ayala, A., Munoz, M.F., and Argüelles, S., Oxid. Med. Cell. Longev., 2014, pp. 360–438.
Jurma, O.P., Hom, D.G., and Andersen, J.K., Free Radic. Biol. Med., 1997, vol. 23, pp. 1055–1066.
Robillard, J.M., Gordon, G.R., Choi, H.B., Christie, B.R., and MacVicar, B.A., PLoS One, 2011, vol. 6, p. e20676.
Abramov, A.Y., Canevari, L., and Duchen, M.R., J. Neurosci., 2003, vol. 23, pp. 5088–5095.
Chakroborty, S., and Stutzmann, G.E., Eur. J. Pharmacol., 2014, vol. 739, pp. 83–95.
Forette, F., Seux, M.L., Staessen, J.A., Thijs, L., Babarskiene, M.R., Babeanu, S., Bossini, A., Fagard, R., Gil-Extremera, B., Laks, T., Kobalava, Z., Sarti, C., Tuomilehto, J., Vanhanen, H., Webster, J., Yodfat, Y., Birkenhäger, W.H., Arch. Intern. Med., 2002, vol. 162, pp. 2046–2052.
Veng, L.M., Mesches, M.H., and Browning, M.D., Mol. Brain Res., 2003, vol. 110, pp. 193–202.
Anekonda, T.S., and Quinn, J.F., Biochim. Biophys. Acta, 2011, vol. 1812, pp. 1584–1590.
McKinney, M. and Jacksonville, M.C., Biochem. Pharmacol., 2005, vol. 70, pp. 1115–1124.
ACKNOWLEDGMENTS
The authors are thankful to the A.S.B.A.S.J.S.M. College of Pharmacy, (Ropar) for providing the necessary research facility.
Funding
No external funding was received.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest. The authors declare that they have no conflict of interest.
Ethical approval. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. This article does not contain any studies with human participants performed by any of the authors.
Rights and permissions
About this article
Cite this article
Pardeep Singh, Kumar, M. & Bansal, N. Azelnidipine Ameliorates Dementia in Streptozotocin Treated Rats: Interplay between Oxidative Stress and Calcium. Neurochem. J. 13, 274–282 (2019). https://doi.org/10.1134/S1819712419030139
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1819712419030139